Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani
{"title":"病例报告:CCND1 RS614367多态性与临床病理特征的关系","authors":"Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani","doi":"10.13005/bpj/2765","DOIUrl":null,"url":null,"abstract":"Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.","PeriodicalId":9054,"journal":{"name":"Biomedical and Pharmacology Journal","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report: The Relationship of CCND1 RS614367 Polymorphism with Clinicopathological Features\",\"authors\":\"Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba, I Gede Krisna Arim Sadeva, Anak Agung Bagus Putra Indrakusuma, Putri Ayu Wulandari, Desak Made Wihandani\",\"doi\":\"10.13005/bpj/2765\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.\",\"PeriodicalId\":9054,\"journal\":{\"name\":\"Biomedical and Pharmacology Journal\",\"volume\":\"29 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical and Pharmacology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13005/bpj/2765\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical and Pharmacology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13005/bpj/2765","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Case Report: The Relationship of CCND1 RS614367 Polymorphism with Clinicopathological Features
Recent studies have shown that the CCND1 rs614367 polymorphism increases the risk of breast cancer and its invasive nature. However, studies evaluating the relationship of the CCND1 rs614367 polymorphism based on the clinicopathology of breast cancer patients in Indonesia were still limited. This study is aimed to determine the CCND1 rs614367 polymorphism in breast cancer and its relationship with the patient's clinicopathology. Methods: This study was a cross-sectional study on 45 samples of breast cancer patients. After collecting demographic and clinical data, PCR and sequencing will be performed on all blood samples to determine the CCND1 rs614367 polymorphism. All variables that have been collected will be analyzed using SPSS version 25.0 to determine the relationship between the CCND1 rs614367 polymorphism and the clinicopathology of breast cancer patients. The CCND1 rs614367 gene polymorphism in breast cancer subjects showed that 25 (55.5%) and 20 (44.5%) subjects had C and T alleles. Subjects aged ≥ 50 years old had a significant 4.45 risk of having the T allele type (p=0.037). In addition, subjects with metastases (M1) were also at a significant 4.89 times risk of having the T allele type (p=0.015). Subjects with histological grade III also had a significantly 4.77 times risk of having the T allele type (p=0.013). In conclusion, there was a significant relationship between CCND1 rs614367 polymorphism and breast cancer subjects' clinopathology features (age, metastasis, and grade). More than half of the subjects with this polymorphism had the C allele.
期刊介绍:
Biomedical and Pharmacology Journal (BPJ) is an International Peer Reviewed Research Journal in English language whose frequency is quarterly. The journal seeks to promote research, exchange of scientific information, consideration of regulatory mechanisms that affect drug development and utilization, and medical education. BPJ take much care in making your article published without much delay with your kind cooperation and support. Research papers, review articles, short communications, news are welcomed provided they demonstrate new findings of relevance to the field as a whole. All articles will be peer-reviewed and will find a place in Biomedical and Pharmacology Journal based on the merit and innovativeness of the research work. BPJ hopes that Researchers, Research scholars, Academician, Industrialists etc. would make use of this journal for the development of science and technology. Topics of interest include, but are not limited to: Biochemistry Genetics Microbiology and virology Molecular, cellular and cancer biology Neurosciences Pharmacology Drug Discovery Cardiovascular Pharmacology Neuropharmacology Molecular & Cellular Mechanisms Immunology & Inflammation Pharmacy.